Recombinant factor VIIa as an antidote for anticoagulant treatment.
D000925:Anticoagulants / Q000009:adverse effects* / Q000037:antagonists & inhibitors; D001384:Azetidines; D001596:Benzylamines; D005167:Factor VII / Q000494:pharmacology / Q000627:therapeutic use*; D015942:Factor VIIa; D005998:Glycine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors; D015801:Helminth Proteins / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000235:genetics / Q000627:therapeutic use; D006470:Hemorrhage / Q000139:chemically induced* / Q000188:drug therapy*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects; D011994:Recombinant Proteins / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000235:genetics / Q000494:pharmacology / Q000627:therapeutic use*
D000925:Anticoagulants; D001384:Azetidines; D001596:Benzylamines; D015801:Helminth Proteins; D010975:Platelet Aggregation Inhibitors; D011994:Recombinant Proteins; C400226:anti-coagulant protein C2, Ancylostoma caninum; C109573:melagatran; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa; D005998:Glycine